Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
Completed
This randomized phase I/II trial studies the side effects and best dose of vaccine therapy and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in treating patients with metastatic breast cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2018
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
Completed
The aim of the study is to assess the safety and immunogenicity of two formulations of the high-dose quadrivalent influenza vaccine compared to the licensed high-dose trivalent influenza vaccine control in healthy elderly subjects aged 65 years of age and above. Primary objectives: * To describe the safety profile of all subjects in each study group. * To demonstrate that the high-dose quadrivalent influenza vaccine induces an immune response (as assessed by HAI geometric mean titers (GMTs) th... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2018
Locations: Not set, Coral Gables, Florida
Conditions: Influenza
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma
Completed
The purpose of this study is to find out what effects (good and/or bad) this new cancer vaccine has on the patient and their cancer, whether it is safe and whether it can help get rid of their cancer (malignant melanoma). We want to check how the patient's immune system reacts, both before and after the vaccine treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2018
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Melanoma (Skin)
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
Completed
The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age population.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
09/26/2017
Locations: Clinical Research of South Florida, Coral Gables, Florida +4 locations
Conditions: Influenza
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Terminated
This randomized phase II trial studies how well docetaxel and prednisone with or without vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from an antigen may help the body build an effective i... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/21/2017
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
Completed
This was a Phase II, randomized, open-label, multicenter study designed to evaluate the immune response to vaccines after administration of 1000 mg of rituximab in subjects with active rheumatoid arthritis (RA) who were receiving background methotrexate (MTX).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2017
Locations: Arthritis Associates of South Florida, Delray Beach, Florida +2 locations
Conditions: Rheumatoid Arthritis
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/26/2017
Locations: GSK Investigational Site, Jacksonville, Florida
Conditions: Influenza
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine and placebo.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
05/04/2017
Locations: GSK Investigational Site, Miami, Florida
Conditions: Influenza
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Completed
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN). Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) \[a mostly T cell-independent humoral response\] and meningococcal polysaccharide dipht... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/01/2017
Locations: Research Site, Fort Lauderdale, Florida +1 locations
Conditions: Relapsing Forms of Multiple Sclerosis
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
Completed
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
04/16/2017
Locations: Not set, Melbourne, Florida
Conditions: Influenza
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
Completed
The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/03/2017
Locations: Optimal Research, Melbourne, Florida
Conditions: Ebola Virus Disease
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
Terminated
DC vaccine manufactured and partially matured using our standard operating procedures, developed in collaboration with the HGG Immuno Group, then administered through imiquimod treated skin will be safe and feasible in children with refractory brain tumors. This will result in anti-tumor immunity that will prolong survival of subjects treated and results will be consistent with the outcomes found for subjects treated by HGG Immuno Group investigators. Study treatment will correlate with laborato... Read More
Gender:
ALL
Ages:
Between 1 year and 29 years
Trial Updated:
03/08/2017
Locations: University of Miami, Miami, Florida
Conditions: Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, High Grade Glioma